

An int22h-related deletion combined with unbalanced X-chromosome results in severe haemophilia A in a female

Pezeshkpoor B, Pavlova A. and Oldenburg J.

Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany

Introduction

Haemophilia A (HA) – a common hereditary bleeding disorder with an incidence of one in 5,000–10,000 male newborns – is caused by a wide spectrum of different mutations in the *factor 8 (F8)* gene. Being an X-linked recessive disorder, females are generally not affected, although they can be carriers of the disorder. In carriers, the disease phenotype mainly depends on the mutation type in *F8* and the degree of X chromosome inactivation. Here, we report the first case of severe HA in a female due to intron 22-related deletions and skewed lyonization.

Patient and Methods

The index patient is a one-year old girl with FVIII:C<1 IU/dl born of a consanguineous marriage with no family history of HA. *F8* was analyzed by the conventional routine technique including: intron 22 (Inv22) and intron 1 inversion PCRS as well as direct sequencing of all 26 exons. Moreover, Multiplex ligation-dependent probe amplification (MLPA) for *F8* was done according to manufacturers instructions. X chromosome inactivation pattern was determined using the *HUMARA* assay¹. The extended intron 22 genetic analysis was performed using the new generation of inverse-Shift (IS-)PCR test².

Results

The patient was negative for both intron 22 (Figure 1) and intron 1 inversion PCRs. Direct sequencing of exons of *F8* and its adjacent intronic regions revealed no mutation. Furthermore, MLPA analysis showed neither duplications nor deletions involving *F8* and the adjacent control regions, which excludes a Turner syndrome as well. As after performing the routine assays no genetic defect was found, we investigated the possibility of the hypothesized of int22h-related deletions by performing the new IS-PCR diagnostic test. This IS-PCR test is mainly used for discrimination of type 1 and type 2 Inv22 pattern. But more importantly the test allows the detection of the int22h-related deletions (Del22). The new diagnostic IS-PCR test revealed a heterozygous Del22 type 1 pattern, resulted from the deletion of int22h-3 (Figure 2). The conventional Inv22 IS-PCR does not detect this deletion and the patients would be misdiagnosed as non-carrier. Furthermore, analysis of the patient's X-inactivation pattern clearly showed preferential inactivation of the unaffected X chromosome (80:20) (data not shown).




Figure 1: Conventional IS-PCR. Inv22 analysis is achieved using three different primers that yields a 487 bp amplicon (ID/IU) for wild-type intragenic allele and a 559 bp amplicon (ED/IU) for Inv22 allele. (A) The Normal *F8* variant; (B) and (C) the Inv22 type 1 and type 2 variants; (D) The index patient is misdiagnosed as non HA carrier.




Figure 2: IS-PCR for diagnostic and complementary test of Inv22 for full characterization of possible int22h-related rearrangements. (A) The normal *F8* wild-type variant h123; (B) HA-associated Inv22 type 1 originating from recombination between *h1* and *h3* and (C) HA-associated Inv22 type 2 originating from recombination between *h1* and *h2*; (D) IS-PCR analysis reveals heterozygous Inv22 type 1 inversion using the diagnostic test but the wild-type pattern after the complementary test indicating the presence of the Del22-related deletion (absence of the 559 bp band).

Conclusion

Here, we present a case of HA caused by a heterozygous Del22 type 1 mutation in combination with non-random X chromosome inactivation that leads to the clinical manifestation of severe HA in a female. The data here shows an example of a rare mechanism leading to HA in females. Moreover, the results presented here underline the limitations of genotyping by Long Distance-PCR approaches^{3,4} and the conventional IS-PCR⁵ test. Diagnostic based on these conventional but widely used tests would lead to misdiagnosis of two group of patients: **first** females with a Dup22 will be diagnosed as an Inv22 carrier and **second** females carrying the Del22 inversion as non-carriers.

References

¹Tost et al Nucleic Acids Res. 2007; ²Rossetti et al. JTH. 2008, ³Bagnall et al. JTH. 2006, ⁴Liu Et al. Blood. 1998, ⁵Rossetti et al. ClinChem. 2005

